PRF makes the farnesyltransferase inhibitor, lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of  lonafarnib on Progeria.

It is PRF’s steadfast mission to find better treatments and a cure for children with Progeria. Lonafarnib has been shown to benefit some aspects of the disease clinically, (Gordon et al, PNAS, 2012) as well as increase lifespan, (Gordon et al, Circulation, 2014) (Gordon et al, JAMA, 2018) but it is not curative. As new compounds are identified with the potential to ameliorate HGPS, we anticipate the need to test these compounds in combination with lonafarnib in vitro and in animal models.

PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.

It is PRF’s steadfast mission to find better treatments and a cure for children with Progeria. Lonafarnib has been shown to benefit some aspects of the disease clinically, (Gordon et al, PNAS, 2012) as well as influence increased estimated lifespan, (Gordon et al, Circulation, 2014) (Gordon et al, JAMA, 2018) but it is not curative. As new compounds are identified with the potential to ameliorate HGPS, we anticipate the need to test these compounds in combination with lonafarnib in vitro and in animal models.

Technical Notes